physostigmine has been researched along with Aprosodia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Derinöz-Güleryüz, O | 1 |
| Baker, LH; Corbett, T; Pazdur, R; Phillips, M; Redman, BG | 1 |
| Duvoisin, RC; Katz, R | 1 |
3 other study(ies) available for physostigmine and Aprosodia
| Article | Year |
|---|---|
Doxylamine succinate overdose: Slurred speech and visual hallucination.
Topics: Adolescent; Cholinesterase Inhibitors; Doxylamine; Drug Overdose; Female; Hallucinations; Histamine H1 Antagonists; Humans; Physostigmine; Speech; Speech Disorders | 2018 |
Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.
Topics: Animals; Antineoplastic Agents; Cognition Disorders; Consciousness Disorders; Drug Evaluation; Drug Evaluation, Preclinical; Gastrointestinal Diseases; Humans; Hydantoins; Mice; Mice, Inbred Strains; Neoplasms; Nitrogen Mustard Compounds; Physostigmine; Speech Disorders | 1987 |
Reversal of central anticholinergic syndrome in man by physostigmine.
Topics: Aged; Ataxia; Central Nervous System Diseases; Child; Cognition Disorders; Delirium; Female; Hallucinations; Humans; Male; Middle Aged; Neostigmine; Parasympatholytics; Parkinson Disease; Physostigmine; Preanesthetic Medication; Scopolamine; Speech Disorders; Trihexyphenidyl | 1968 |